Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 11/20 | 0.63 |
| ▸ | WNT3A | P56704 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SCD | O00767 | 1/20 | 0.51 |
| ▸ | MET | P08581 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23136930 | 0.88 | CSNK1D (0.58) | CSNK1DWNT3ACYP3A4MEN1KMT2A | |
| SCHEMBL23136935 | 0.86 | CSNK1D (0.78) | CSNK1DWNT3ACYP3A4KDM4ELMNA | |
| SCHEMBL23136894 | 0.84 | CSNK1D (0.68) | CSNK1DWNT3ACYP3A4KDM4ELMNA | |
| SCHEMBL23136936 | 0.81 | CASP3 (0.56) | MAPTDYRK1AMEN1KMT2ASCD | |
| SCHEMBL23136932 | 0.81 | MAPT (0.71) | CSNK1DWNT3ACYP3A4KDM4ELMNA | |
| SCHEMBL4914800 | 0.81 | CSNK1D (0.87) | CSNK1DWNT3ACYP3A4KDM4EMAPT | |
| SCHEMBL17287785 | 0.79 | CSNK1D (1.00) | CSNK1DWNT3ACYP3A4MEN1KMT2A | |
| SCHEMBL17287759 | 0.75 | CSNK1D (0.88) | CSNK1DWNT3ACYP3A4 | |
| SCHEMBL17287673 | 0.74 | CSNK1D (1.00) | CSNK1DWNT3ACYP3A4POLBMAPT | |
| SCHEMBL23135804 | 0.74 | DYRK1A (0.67) | CSNK1DKDM4EPOLBMAPTDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087290-A1 | COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | ENCEFA (FR) | 2021-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087290-A1 | COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | CD38, TRPC1, TRPC4 | CSNK1D 4334/4885WNT3A 4484/4885CYP3A4 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.